Summary
The Canadian Cancer Society is calling on governments to lower the starting age for colorectal cancer screening from 50 to 45, citing a sharp rise in diagnoses among Canadians under 50. Experts say earlier screening could prevent thousands of cases and deaths while reducing the financial burden of late-stage cancer.
The Canadian Cancer Society (CCS) is calling on provincial and territorial governments to lower the starting age for colorectal cancer screening from 50 to 45. The recommendation, released on March 11, 2026, comes as medical evidence reveals a sharp increase in the disease among younger adults, a group previously considered “low risk.”
Colorectal cancer is currently the fourth most commonly diagnosed cancer in Canada and the second leading cause of cancer-related death. However, when detected in its earliest stages, the survival rate is approximately 90%.
A Growing Risk for the “Under 50” Population
Over the last several decades, the incidence of colorectal cancer in Canadians under 50 has skyrocketed. According to the CCS, people in this age group are now 2 to 2.5 times more likely to be diagnosed than previous generations were at the same age.
“Current colorectal cancer screening guidelines are failing to meet the evolving needs of people under 50,” says Brandon Purcell, Advocacy Manager of Prevention and Early Detection at the CCS. “When the context changes, our healthcare systems must change with it.”
New modeling suggests that lowering the screening age to 45 across Canada could prevent 15,000 cancer cases and 6,100 deaths over the next 45 years.
The Problem with Late Diagnosis
One of the most concerning trends in the report is that younger adults are frequently diagnosed at later stages (Stage III or IV). Because they fall outside current screening guidelines, symptoms are often brushed off or attributed to minor issues like hemorrhoids until the cancer has spread.
For Wylie Butler, who was diagnosed at 48, the change is deeply personal. He spent months ignoring occasional bleeding before a diagnosis led to three surgeries and a battle with sepsis. “If screening had started at 45, my cancer might have been found sooner and I could have avoided some of the complications I went through,” Butler says.
The Economic and Clinical Case for 45
The CCS argues that lowering the age is not just a medical necessity but a preventative measure that saves the healthcare system money by catching precancerous polyps before they turn into full-blown cancer.
Screening typically starts with a Fecal Immunochemical Test (FIT), a simple, non-invasive stool test that can be done at home. If blood is detected, a colonoscopy is then used to confirm the diagnosis or remove polyps.
Despite the evidence, no provincial government has yet officially expanded eligibility to the age of 45. The CCS is urging these jurisdictions to act swiftly and provide the resources needed to ensure timely access to these life-saving tests.
The “Hidden” Cost: $33,000 and Climbing
While Canada’s healthcare system is publicly funded, a cancer diagnosis carries a staggering private price tag. A December 2024 report from the Canadian Cancer Society reveals that the average cancer patient in Canada faces $33,000 in lifetime out-of-pocket expenses and lost income. These costs include:
- Lost Wages: Patients and caregivers often have to reduce work hours or leave the workforce entirely during treatment. This can be particularly devastating for people in the prime of their careers.
- Medical Gaps: Expenses for certain prescription drugs, homecare, and medical supplies not covered by provincial plans.
- Travel and Logistics: Significant costs for transportation and accommodation, particularly for those in rural areas traveling to urban cancer centers.
The Financial Toll of the Wait
The burden is compounded by the “private cost of public queues.” A March 2026 study by the Fraser Institute found that medical wait times alone cost Canadians more than $4.2 billion in lost wages and productivity last year.
The study estimates that the average patient waiting for treatment loses approximately $3,043 in income due to their inability to work effectively while in medical limbo. “Canadians are paying twice for health care,” notes Nadeem Esmail, director of health policy studies at the Fraser Institute. “They’re paying through their tax dollars… and then they’re paying with their own time and productivity while care is delayed.”
As the landscape of cancer shifts, the traditional “wait until 50” rule appears increasingly outdated. Lowering the screening age offers more than just a medical advantage; it provides a vital economic safeguard for young families who can least afford the devastating $33,000 financial hit of a late-stage diagnosis.
Subscribe to The Health Insider newsletter for more evidence-based insights delivered straight to your inbox.
~ Read more from The Health Insider ~
- Colorectal Cancer Rising in Younger Adults: Experts Urge Screening at 45
The Canadian Cancer Society urges governments to lower the colorectal cancer screening age to 45 as diagnoses continue rising among Canadians under 50. - GLP-1s and Bone Health: Potential Risks for Non-DiabeticsNew studies reveal a 22% higher osteoporosis risk for non-diabetics on GLP-1s. Learn how these weight-loss drugs may impact your skeletal strength.
- Protecting Canada’s Kids: The Hidden Risk in Your Child’s Favourite Cartoon SnacksA Canadian report finds many kids’ snacks with cartoon characters are high in sugar, sodium or fat, raising concerns about food marketing to children.
- At-Home Sperm Testing: As Accurate As In-Clinic?Skip the clinic. Learn how Canadian mail-in kits bypass the “one-hour rule” with 99% accuracy and which provincial credits cover the cost.
- Endometriosis and the Immune System: What New Research Is ShowingNew research suggests people with endometriosis may face higher odds of autoimmune disease. Here’s what scientists know so far.
- Beyond Red & Green: New Tech for Colour BlindnessOver 1.5 million Canadians live with colour blindness. Discover the science, daily challenges, and the high-tech tools changing how they see.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
